The prolonged clinical experience with the antivascular endothelial growth factor (VEGF) or its receptor (VEGFR) has proven its effect in the treatment of several types of cancers. However, treatment can be accompanied by notable adverse effects like proteinuria and hypertension. In recent years, the toxic effects of anti-VEGF therapy in the kidney have increased. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now well recognized.
Vascular endothelial growth factor (VEGF) is an important signalling protein involved in angiogenesis, a key process in cancer growth and dissemination. Thus, inhibition of VEGF signalling has become a target for antitumour therapy and many new drugs are being developed. Antiangiogenesis agents are among the most commonly used anticancer agents in oncology practice today. Based on…
